Cytosorbents (CTSO) Payables (2010 - 2026)

Cytosorbents (CTSO) has reported Payables for 17 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 41.01% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (down 41.01% YoY), and the FY2025 full-year result was $2.9 million, down 14.1% from the prior year.
• Payables fell to $2.0 million in Q2 2026 per CTSO's latest filing, from $3.1 million in the prior quarter.
• Across five years, Payables topped out at $4.8 million in Q1 2022 and bottomed at $1.7 million in Q4 2022.
• Historically, Payables has averaged $2.9 million across 5 years, with a median of $3.0 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Payables soared 187.66% in 2022, then plunged 41.01% in 2026.
• Over 5 years, Payables stood at $1.7 million in 2022, then jumped by 129.71% to $3.8 million in 2023, then fell by 12.16% to $3.3 million in 2024, then dropped by 14.1% to $2.9 million in 2025, then sank by 30.22% to $2.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $2.0 million, $3.1 million, and $2.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.